CHICAGO--(BUSINESS WIRE)--CDG Therapeutics, Inc. (www.cdgti.com) today announced results from a clinical Phase I human trial of a novel platform technology utilizing p28, a synthetic, Azurin-derived peptide. Fifteen refractory (Stage IV) solid tumor patients with p53+ lesions were enrolled in an escalating, five-dose level (.83, 1.66, 2.5, 3.33, and 4.16 mg/kg) Phase I trial to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics (PK/PD) of p28 as a single agent. The data was presented at this week’s American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
